Diarylacetylene STAT3 Inhibitors for Lower-Toxicity Tumor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antitumor drugs suffer from significant toxic side effects and low response rates due to STAT3 activation in various human malignancies, limiting treatment options for cancer patients.
Innovation Solution
Development of a novel class of diarylacetylene compounds that inhibit STAT3 activation, offering potent antiproliferative effects against diverse tumor cells with minimal toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antitumor drugs (paclitaxel, doxorubicin, vincristine) are used to achieve broad-spectrum anticancer activity, then anticancer efficacy is improved, but toxic side effects increase significantly
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (STAT3 signaling pathway) that drives cancer progression, rather than using broad-spectrum cytotoxic drugs. By designing diarylacetylene compounds that specifically inhibit STAT3 activation, the invention achieves anticancer efficacy while avoiding the non-specific toxicity of conventional chemotherapy agents.
Solution Approach 2:
The diarylacetylene compounds act as intermediary molecules that block the interaction between cytokines/growth factors and STAT3, preventing the downstream carcinogenic events. This intermediary approach allows selective inhibition of the cancer-driving pathway without affecting normal cellular functions that depend on other signaling pathways.
2Object-affected harmful factors
If diverse targeted cancer therapies are used to reduce toxic side effects, then safety is improved, but response rates decrease or drug resistance develops
Solution Approach 1:
The diarylacetylene compounds demonstrate universal efficacy across multiple cancer types (lung, breast, gastric, liver, pancreatic, prostate cancers, leukemia, etc.) by targeting the common STAT3 signaling pathway that is constitutively activated in approximately 70% of human malignancies. This multi-functional approach maintains high response rates while avoiding the limitations of cancer-type-specific therapies.
Solution Approach 2:
The patent modifies the chemical structure parameters of the compounds (as shown in formulas I-V with various R1, R2, W, X, Y, G, Q, V substitutions) to optimize STAT3 inhibition potency and pharmacological properties, achieving nanomolar range IC50 values while maintaining broad-spectrum activity across different malignancies.
3Reliability
If STAT3-targeted therapies are developed to achieve high efficacy, then anticancer activity is improved, but compound complexity increases
Solution Approach 1:
The diarylacetylene compounds incorporate specific local structural features (diarylacetylene core with tailored substituents) that are critical for STAT3 binding and inhibition. The molecular design focuses complexity only where needed (at the STAT3 interaction interface) while keeping other portions of the molecule simple and drug-like, achieving high efficacy without excessive overall complexity.
Data Source
AI summary
The disclosure provides diarylacetylene compounds, their preparation methods, and applications. These compounds contain a biologically active isoindolinyl-piperazinyl urea core moiety. Further chemical modification of this core generates numerous compounds with higher biological activity, or their pharmaceutically acceptable salts, hydrates, solvates, metabolites, prodrugs, or pharmaceutical compositions. This expands the broad application potential of such compounds in biomedicine and the prospects for pharmaceutical formulation development. This class of compounds can target the STAT3 protein. At low doses (nanomolar concentrations), they significantly inhibit the proliferation of various tumor cells, including lung cancer, breast cancer, liver cancer, pancreatic cancer, and gastric cancer cells. They also effectively suppress the growth of transplanted tumors in mice. These results indicate that this class of compounds holds promise for development into drugs for the prevention and/or treatment of tumors and other diseases associated with abnormal STAT3 signaling.